insider trading  sandor victor  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  sandor victor select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm na array biopharma inc arry sandor victorchief medical officer   direct view option award  pm na array biopharma inc arry sandor victorchief medical officer   direct view exercise  pm nana array biopharma inc arry sandor victorchief medical officer   direct view tax withholding  pm nana array biopharma inc arry sandor victorchief medical officer   direct view exercise  pm na array biopharma inc arry sandor victorchief medical officer   direct view tax withholding  pm nana array biopharma inc arry sandor victorchief medical officer   direct view option award  pm na array biopharma inc arry sandor victorchief medical officer   direct view option award  pm na array biopharma inc arry sandor victorchief medical officer   direct view exercise  pm nana array biopharma inc arry sandor victorchief medical officer   direct view tax withholding  pm nana array biopharma inc arry sandor victorchief medical officer   direct view exercise  pm na array biopharma inc arry sandor victorchief medical officer   direct view option award  pm nana array biopharma inc arry sandor victorchief medical officer   direct view option award  pm na array biopharma inc arry sandor victorchief medical officer   direct view exercise  pm nana array biopharma inc arry sandor victorchief medical officer   direct view tax withholding  pm nana array biopharma inc arry sandor victorchief medical officer   direct view exercise  pm na array biopharma inc arry sandor victorchief medical officer   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  victor sandor of array biopharma inc executive profile   array biopharma inc  arry overviewexecutive compensationinsider activitykey executivesboard of directorscommittees key executives  victor sandor victor sandor chief medical officer profile connections biography dr sandor  has served as our chief medical officer since september  prior to joining array dr sandor was senior vice president for global clinical development at incyte corporation a position he held beginning may  after first joining incyte in february  as its vice president global oncology drug development prior to joining incyte dr sandor was vice president and chief medical officer for oncology at biogen idec from november  to february  he previously held positions of increasing responsibility in oncology product development at astrazeneca from september  to november  where he played an important role in the registration of arimidex for adjuvant use the development of faslodex and the development of several early stage programs through proof of concept board membership victor sandor is not a member of any boards   victor sandor  array biopharma inc  zoominfocom microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft victor sandor  florence nj  intelius sign in we found victor sandor in florence nj victor sandor intelius found that victor sandor is a male from florence nj we have connected them to  address  phones and  relative or associate get report now victor has lived in florence nj victors relatives mary sandor victor sandor gendermale get report now want to know more about victor get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about victor or use our people search engine to find others get background check on victor sandor get a criminal check on victor sandor get a public record report on victor sandor get a people search report on victor sandor victor sandors contact information known cities lived in find out where victor sandor has lived as well as victor sandors phone numbers and email addresses victor sandor has lived in  states new jersey address for victor sandor  e  s florence nj has lived in florence nj get full address report phone numbers associated with victor sandor    florence nj    florence nj get full phone report email addresses associated with victor sandor vrnet get email report victor sandors social network and potential email matches find out potential social network profiles and potential email usernamed for victor sandor victor sandors known social networks and potential email matches find all of victor sandors social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches victor sandor username matches victorsandor sandorvictor victorsandor sandorvictor victorsandor sandorvictor victorsandor sandorvictor vsandor popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches v sandor intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here victor e sandor  englewoodnj  vic sandor   people finder results people finder enter first name  last name all states alabama alaska arizona arkansas california colorado connecticut delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania puerto rico rhode island south carolina south dakota tennessee texas utah vermont virginia washington washington dc west virginia wisconsin wyoming people finder results for vic sandor results from publicrecords showing top  of  results premium public records for vic sandor found in this find people section originate from public directories available on the internet to their subscribers people finder results may contain information about relatives  classmates if you are vic sandor and want to change or delete your or your relatives classmates record please contact the data provider directly instantpeoplefindercom caches the people finder results and after optout with the data provider the results will automatically disappear after few days fullnameaddressesphone dobrelativesmore details englewood njvictor e sandor  addresss found englewoodnjtenaflynj  phone numbers found  age yrs   carmen sandorkevin sandorainsley sandor get public records property records  more   williamsburg vavictor a sandor  addresss found williamsburgvarockvillemdbethesdamdkennett squarepabelmontma  phone numbers found  age yrs   johanne gibeau get public records property records  more   albuquerque nmvictor sandor  addresss found albuquerquenmsanta fenmrio ranchonmontariocaglendoraca  phone numbers found  age yrs   summer izayjoroybal izay get public records property records  more   edison njvicki j sandor  addresss found edisonnj  phone numbers found  age yrs   nicholas sandorncholas sandorchristina santoro get public records property records  more   woodbridge njvictor j sandor  addresss found woodbridgenjcranburynjalamogordonmmonroe townshipnj  phone numbers found    dustin sandorvaughn sandorhelen sandordouglas sandor get public records property records  more   ocean city mdvictoria ivaoua sandor  addresss found ocean citymdwashingtondcrockvillemd  phone numbers found  age yrs   usn sandorjohn sandor get public records property records  more   senecaville ohvictor andrew sandor  addresss found senecavilleoh  phone numbers found  age yrs   alvina sandornancy preisachgaza sandor get public records property records  more   glenview ilvicki sandor  addresss found glenviewilchicagoilnorthbrookil  phone numbers found    mihai sandorviorica sandormihaela sandor get public records property records  more   phoenix azvictoria l sandor  addresss found phoenixazalbuquerquenmmoreno valleycacosta mesacariversideca  phone numbers found  age yrs   william sargentjames kaufmanrobert kaufmanmelissa forbesrichard kaufman get public records property records  more   sacramento cavictor sandor  addresss found sacramentocaorangevaleca  phone numbers found    ioan sandorana sandor get public records property records  more   public comments for vic sandor  public comments related to name vic sandor are submitted by users you are solely responsible for your use of this section on instantpeoplefindercom and use them at your own risk by using these forums and interactive areas you agree not to post transmit distribute store create or otherwise publish any messages that violate our terms  conditions leave a public comment for vic sandor please enable javascript to view the comments powered by disqus blog comments powered by disqus no results found your people finder query  vic sandor  did not yield any results suggestions  make sure search query is spelled correctly  try a different search query  try to be more general or try intelius premium people finder first name last name  state pages usa people finder search read our blog news  real time people search tool  privacy policy terms  conditions benefits of service how to use about us contact us follow us become a fan and connect with evergrowing community of people finder searchers share your thoughts and find out what instant people finder is up to next find people with one click find people information instantly easy to use people finder for free using public records addresses phone numbers yellow pages and background check from email to address search or reverse phone number to a general people locator  we have all the free people finder engine bases covered so give it a try and get started with the most basic surname search on free people finder page browse name directory by lastname abcdefghijklmnopqrstuvwxyz recent updates yesterday        copyright  trademark  instantpeoplefindercom  instant people finder all rights reserved instant people finder disclaimer for this page victor e sandor  englewoodnj  vic sandor   people finder results most records for people finder search people free  background check for vic sandor are dynamically obtained in realtime any private information consisting of email addresses street addresses phone numbers etc for vic sandor are gathered from an extensive list of free web sources available on major people search engines  social networks unavailable  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries this feature is temporarily unavailable copyright – fmr llc  all rights reserved  terms of use privacy security site map  arry stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsarry array biopharma inc    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade option chain price history download to csv file download to excel file log in for more news expand all collapse all technical reports on biotech equities  opko health array biopharma immunomedics and tg therapeutics pr newswire –  am et  new york july   if you want a stock review on opk arry immu or tgtx then come over to httpdailystocktrackercomregister and sign up for your free customized report today httpdailystocktrackercomregister opko health  on wednesday shares in miami florida headquartered opko health inc opk gained  ending the day at  the stock recorded a trading volume of  mill briefamgen and array biopharma announce preclinical license and collaboration agreement reuters –  am et  array biopharma inc arry  amgen amgn and array biopharma arry announce preclinical license and collaboration agreement in inflammation  array biopharma arry  under terms of agreement amgen amgn and array will collaborate on preclinical development with array leading medicinal chemistry work amgen and array biopharma announce preclinical license and collaboration agreement in inflammation pr newswire –  am et  thousand oaks calif and boulder colo we are pleased to enter this collaboration with array that builds on our continued focus in inflammation one of amgens amgn key strategic areas of interest said flavius martin md vice president of research inflammation and oncology at amgen pharma stocks taking measures to boost growth pr newswire –  am et  palm beach florida july   biotech and big pharma stocks have been a tear of late causing the spdr sp biotech etf to edge towards annual highs briefarray biopharma submits new drug applications to fda reuters –  am et  array biopharma inc arry  array biopharma arry submits new drug applications to fda for binimetinib and encorafenib in advanced melanoma array biopharma submits new drug applications to fda for binimetinib and encorafenib in advanced melanoma pr newswire –  am et  boulder colo premarket technical recap on biotech stocks  array biopharma catabasis pharma cerulean pharma and immunomedics pr newswire –  am et  new york june   if you want a stock review on arry catb ceru or immu then come over to httpdailystocktrackercomregister and sign up for your free customized reports today httpdailystocktrackercomregister array biopharma  boulder colorado headquartered array biopharma incs arry shares surged  finishing tuesdays trading session at  a total volume of  millio array biopharma to present at the goldman sachs th annual global healthcare conference pr newswire –  am et  boulder colo about array biopharma arry array biopharma inc arry is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer briefono pharmaceutical concludes a license agreement with array biopharma related to mek inhibitor and braf inhibitor reuters –  am et  ono pharmaceutical co ltd ophlf  says it concluded a license agreement with array biopharma inc arry to develop and commercialize binimetinib a mek inhibitor and encorafenib a braf inhibitor in japan and south korea briefarray biopharma  ono pharmaceutical announce partnership for two novel oncology compounds reuters –  am et  array biopharma inc arry  array biopharma arry  ono pharmaceutical co ltd announce license development  commercialization partnership for  novel oncology compounds binimetinib and encorafenib  array biopharma arry says array to receive  million upfront payment and up to  million in additional development and commercial milestones array biopharma and ono pharmaceutical co ltd announce a license development and commercialization partnership for two novel oncology compounds binimetinib and encorafenib pr newswire –  am et  boulder colo and osaka japan  array biopharma inc arry and ono pharmaceutical co ltd today announced a license development and commercialization partnership for arrays latestage novel oncology compounds binimetinib and encorafenib  million and retains exclusive commercialization rights for binimetinib and encorafenib in the united states canada and israel briefarray biopharma and bristolmyers squibb announce strategic collaboration reuters –  am et  array biopharma inc arry  array biopharma and bristolmyers squibb bmy announce strategic collaboration  bristolmyers squibb co bmy says under terms of agreement array and bristolmyers squibb bmy will jointly support study with array acting as sponsor  bristolmyers squibb co bmy  collaboration to investigate safety tolerability and efficacy of arrays investigational mek inhibitor binimetinib array bipharma shares jump  in premarket trade marketwatch –  am et  array biopharma and bristolmyers to collaborate on treatment for colorectal cancer marketwatch –  am et  array biopharma and bristolmyers squibb announce strategic collaboration pr newswire –  am et  boulder colo opdivo as well as binimetinib in combination with the opdivo  yervoy regimen under the terms of the agreement array and bristolmyers squibb bmy will jointly support the study with array acting as the sponsor array biopharma and bristolmyers squibb announce strategic collaboration business wire –  am et  novel combinations of binimetinib opdivo® and yervoy® to be studied in colorectal cancer patients array biopharma arry and bristolmyers squibb company today announced the companies have entered into a clinical research collaboration to investigate the safety tolerability and efficacy of array’s investigational mek inhibitor binimetinib in combination with bristolmyers squibb’s opdivo and  briefarray biopharma q loss per share  reuters –  am et  array biopharma inc arry  array biopharma reports financial results for the third quarter of fiscal   q loss per share   q earnings per share view   thomson reuters ibes  q revenue  million versus ibes view  million  array biopharma inc arry  is on track to file an nda for columbus in june or july  array biopharma reports financial results for the third quarter of fiscal  pr newswire –  am et  boulder colo columbus phase  trial positive part  results announcedon may   array announced topline results from part  of the phase  columbus study evaluating binimetinib a mek inhibitor and encorafenib a braf inhibitor in patients with brafmutant advanced unresectable or metastatic melanoma briefarray biopharma announces positive topline results from part  of the phase  columbus study of binimetinib and encorafenib reuters –  pm et  array biopharma inc arry  array biopharma arry announces positive topline results from part  of the phase  columbus study of binimetinib and encorafenib for brafmutant melanoma  array biopharma inc arry  new drug application filing on track for june or july   array  median pfs for patients on combination of binimetinib plus encorafenib  months versus  months for patients on encorafenib array biopharma announces positive topline results from part  of the phase  columbus study of binimetinib and encorafenib for brafmutant melanoma pr newswire –  pm et  boulder colo brafmutant melanoma said keith t flaherty md director of the termeer center for targeted therapy massachusetts general hospital and professor of medicine harvard medical school page page   next  todays and upcoming events aug  arry to announce q earnings before market unconfirmed past events last  days no events in the past  days data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top vz log in for events urbn urbn syna ll hp log in for events alks cvrr cvrr esnd find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  pm et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map    array biopharma appoints victor sandor md as chief medical officer array biopharma appoints victor sandor md as chief medical officer clinical oncology expert joins as company advances latestage clinical programs sep    et from array biopharma inc boulder colo sept   prnewswire  array biopharma inc nasdaq arry a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients with cancer today announced the appointment of victor sandor md as chief medical officer dr sandor will be responsible for leading clinical medical and regulatory strategy and operations across the array portfolio including binimetinib a mek inhibitor in phase  trials for ovarian cancer and melanoma and filanesib a ksp inhibitor for multiple myeloma dr sandor brings a wealth of experience in oncologyhematology drug development following a successful track record in leadership positions at premier biopharmaceutical and pharmaceutical companies including incyte biogen and astrazeneca in these roles he was instrumental in bringing products such as jakafi® ruxolitinib arimidex® anastrozole and faslodex® fulvestrant injection to the market and was responsible for advancing these and several other targetedand immunotherapies through clinical development for a broad range of cancer indications dr sandors leadership experience and vision will strengthen our clinical development efforts as we advance our latestage whollyowned assets toward commercialization said ron squarer chief executive officer array biopharma with the possible nearterm return of binimetinib to array his expertise will have significant impact on our longterm success i am pleased to join the array team at such an exciting time in the companys evolution said dr sandor in addition to the impressive portfolio of clinicalstage assets in development by arrays partners i look forward to focusing on the development of binimetinib and filanesib which each target patient populations with significant unmet medical need dr sandor has more than a decade of experience in the pharmaceutical and biotechnology industries prior to joining array he was senior vice president for global clinical development at incyte corporation in this role he was instrumental in the development approval and commercialization of the first jak inhibitor while leading clinical development clinical operations medical affairs and biostatistics across the entire portfolio including responsibility for several novel mechanisms including pik cmet and ido inhibitors prior to incyte dr sandor was vice president and chief medical officer for oncology at biogen idec he previously held positions of increasing responsibility in oncology product development at astrazeneca where he played an important role in the registration of arimidex for adjuvant use the development of faslodex and the development of several early stage programs through proof of concept dr sandor received his md cm from mcgill university in montreal canada and completed his fellowship in medical oncology at the national institutes of health in bethesda maryland dr sandor will replace arrays prior chief medical officer michael needle md who is leaving the company to pursue other opportunities about array biopharma array biopharma inc is a biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer seven phase  studies are in progress or are planned to begin this year these programs include the whollyowned hematology drug filanesib arry for multiple myeloma and two partnered cancer drugs selumetinib astrazeneca and binimetinib mek  novartis for more information on array please go to wwwarraybiopharmacom array biopharma forwardlooking statement this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements about the potential return of binimetinib to array arrays clinical development plans and the contribution of dr sandor to advancing arrays drug development pipeline these statements involve significant risks and uncertainties including those discussed in our annual report filed on form k for the year ended june   and in other reports filed by array with the securities and exchange commission because these statements reflect our current expectations concerning future events our actual results could differ materially from those anticipated in these forwardlooking statements as a result of many factors these factors include but are not limited to our ability to predict determinations to be made by regulatory agencies and novartis relating to the return of binimetinib to array as a result of novartis transaction with glaxosmithkline our ability to continue to fund and successfully progress internal research efforts and to create effective commercially viable drugs our ability to achieve and maintain profitability the extent to which the pharmaceutical and biotechnology industries are willing to inlicense drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities our ability to outlicense our proprietary candidates on favorable terms risks associated with our dependence on our collaborators for the clinical development and commercialization of our outlicensed drug candidates the ability of our collaborators and of array to meet objectives tied to milestones and royalties and our ability to attract and retain experienced scientists and management we are providing this information as of september   we undertake no duty to update any forwardlooking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements contact tricia haugeto   thaugetoarraybiopharmacom source array biopharma inc related links httpwwwarraybiopharmacom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more nov    et preview array biopharma reports financial results for the first quarter of fiscal  jul    et preview array biopharma to report financial results for the fourth quarter and full year of fiscal  on august   my news release contains wide tables view fullscreen read more mar    et array biopharma to present at the goldman sachs th annual mar    et shalini sharp joins array biopharma board of directors mar    et array biopharma provides nemo update looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search array biopharma  management team contact us  careers go menu homeabout usmanagement teamboard of directorscontact uspipelinebinimetinibencorafenib lgxselumetinibother programsclinical trialsdiscovery collaborationsarray discovery capabilitiesselected collaborationscontact uspublicationsinvestorsstock informationnews  eventsfinancialscorporate governanceshareholder services search go management team ron squarerchief executive officer ron squarer has served as chief executive officer and a member of the array board of directors since april  mr squarer has extensive commercial development and executive leadership expertise from a greater than two decade career in the biopharmaceutical industry prior to this mr squarer held positions of increasing responsibility with hospira inc a global pharmaceutical and medical device company most recently serving as senior vice president chief commercial officer where he was responsible for delivering  billion in annual revenue  mr squarer joined hospira from mayne pharma where he served as senior vice president global corporate and business development when mayne was sold to hospira in   prior to mayne pharma mr squarer held senior management roles at both pfizer inc and at smithkline beecham pharmaceuticals now glaxosmithkline in the us and europe mr squarer currently serves as a member of the board of directors of retrophin inc mr squarer holds an mba from the kellogg school of management northwestern university and a bachelor’s degree in biochemistry from the university of california berkeley jason haddockchief financial officer mr haddock joined array as chief financial officer in july  he has more than  years of financial and operational experience in the biopharmaceutical industry mr haddock held leadership positions of increasing responsibility at bristolmyers squibb a global pharmaceutical company with a strong focus on immunooncology therapies during that time he served in variety of accounting planning commercial analytical and business development capacities for highgrowth business units including head of finance for the worldwide commercialization and medical teams mr haddock also served as executive director for the us pharmaceutical unit where he focused on designing and implementing a completely new business model and operations to capitalize on future product portfolio changes and market developments mr haddock most recently served as chief financial officer and chief operating officer of berg health an oncology focused research diagnostics and development company where he oversaw the implementation of financial and operational processes procedures and policies to transform and scale the company’s practices as it planned for growth and corporate evolution mr haddock earned his undergraduate degree in accountancy from illinois state university and is a certified management accountant he holds an mba from washington university in st louis where he completed the executive program john r moorevice president  general counsel mr moore has served as vice president and general counsel since may  and as secretary since october  prior to joining array mr moore was an associate for three years with the law firm wilson sonsini goodrich  rosati where he negotiated transactions involving technology intellectual property matters and products prior to that mr moore was an associate with the law firms kenyon  kenyon and arnold white  durkee where he focused on intellectual property matters he currently serves on the board of directors of nivalis therapeutics nasdaq nvls mr moore received a jd from the university of north carolina at chapel hill an ms in biochemistry from the university of illinois at urbanachampaign and a bs in chemistry from the university of north carolina at chapel hill victor sandor mdchief medical officer dr victor sandor has served as chief medical officer since september   dr sandor has more than a decade of experience in the pharmaceutical and biotechnology industries  prior to joining array he was senior vice president for global clinical development at incyte corporation  in this role he was instrumental in the development approval and commercialization of jakafi® ruxolitinib the first jak inhibitor while leading clinical development clinical operations medical affairs and biostatistics across the entire portfolio including responsibility for several novel mechanisms including pik cmet and ido inhibitors  prior to incyte dr sandor was vice president and chief medical officer for oncology at biogen idec  he previously held positions of increasing responsibility in oncology product development at astrazeneca where he played an important role in the registration of arimidex® anastrozole for adjuvant use the development of faslodex® fulvestrant injection and the development of several early stage programs through proof of concept  dr sandor received his md cm from mcgill university in montreal canada and completed his fellowship in medical oncology at the national institutes of health in bethesda maryland andrew robbinschief operating officer andrew robbins has served as chief operating officer since march  and previously served as senior vice president of commercial operations since july  mr robbins has extensive commercial development and strategic leadership expertise from a year career in the pharmaceutical industry with a specific focus on oncologyhematology products most recently he was at hospira inc where he served as general managervice president of the us alternate site business unit focused on the sales of pharmaceuticals and medical devices to outpatient oncology surgery pain and dialysis customers in this role he led a team of approximately  employees including a national sales force to deliver over  million in annual revenue prior to this he was vice president of corporate development and was responsible for global branded pharmaceutical marketing and business development research and development portfolio prioritization global strategy and corporate venture investing during his tenure he designed and executed a strategy to build a latestage hematologyoncology and acute pain pipeline via licensing and acquisition mr robbins also served on the board of directors for three venturebacked healthcare companies two of which were focused on innovative hematologyoncology products before hospira mr robbins was a commercial leader within pfizer’s oncology unit responsible for shepherding a portfolio of  preclinical and clinical stage products through development using a “fasttopatient” approach several of these products including sutent® sunitinib inlyta® axitinib and xalkori® crizotinib have been commercialized mr robbins holds an mba from the kellogg school of management northwestern university and a bachelors degree from swarthmore college nicholas a saccomano phdchief scientific officer dr nicholas a saccomano has served as chief scientific officer since may   dr saccomano is a seasoned leader with  years of experience in pharmaceutical and biotechnology research and development with expertise in discovery research clinical development portfolio strategy technology and clinical candidate licensing and scientific partnering  dr saccomano most recently served as chief technology officer at somalogic inc and as chief scientific officer at bend research inc  while at pfizer inc dr saccomano held positions of increasing responsibility including senior vice president in the rd organization and vice president of discovery technology  as head of discovery technology he managed and developed a diverse set of enabling technologies used broadly across the drug discovery pipeline  during his tenure he also directed medicinal sciences drug discovery and strategic alliances  dr saccomano obtained his phd in chemistry from columbia university under the direction of professor gilbert stork kimberly popevice president human resources ms kimberly pope has served as vice president of human resources since january   ms pope has extensive human resource business and leadership experience in the healthcare and technology industries including  years with abbott laboratories and hospira inc she started at abbott laboratories in the talent acquisition group and later transitioned to hospira  at hospira ms pope held leadership positions of increasing responsibility including director of human resources for global marketing for global information technology and for global operations  in the operations role she was responsible for the hr business partner relationships for the global api pharmaceutical business program management global engineering manufacturing science and technology and the technical professional development program  in addition her business strengths allowed her to play a key role in a major acquisition in india including the building of the largest injectable medicine facility in the world  most recently ms pope was group vice president human resources at idex corporation a global leader in applied engineering solutions specializing in health and science technologies among other diversified products  in her role she supported a global team of  associates across  sites where she had responsibility for talent management talent acquisition organizational effectiveness and driving culture change throughout the business ms pope holds a bachelor of business administration degree from the university of iowa and is a senior professional in human resources from the human resource certification institute  about usmanagement teamboard of directorscontact us homeabout usmanagement teamboard of directorscontact uspipelinebinimetinibencorafenib lgxselumetinibother programsclinical trialsdiscovery collaborationsarray discovery capabilitiesselected collaborationscontact uspublicationsinvestorsstock informationnews  eventsfinancialscorporate governanceshareholder services    array biopharma all rights reserved privacy policy  legal